ArticleFrontiers in oncology2026
Case Report: Synchronous germline
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Synchronous occurrence of choroidal melanoma and clear cell renal cell carcinoma (ccRCC) is exceptionally rare and traditionally suspicious for Case presentation: A 64-year-old Chinese male with a 2-year history of progressive vision loss in his right eye was found to have an intraocular melanocytic tumor by multimodal imaging. Staging PET/CT incidentally detected a hypermetabolic mass in the right kidney. Guided by imaging and multidisciplinary team (MDT) discussion, the patient underwent right eye enucleation followed by right partial nephrectomy. Histopathology and immunohistochemistry supported two independent localized primary tumors: mixed-cell choroidal melanoma (AJCC 8th edition stage II, pT2aN0M0) and ccRCC (pT1bN0M0, WHO/ISUP grade 2). Postoperative comprehensive genomic profiling provided supportive molecular evidence, showing a Conclusion: This case illustrates that multimodal imaging and multidisciplinary assessment can guide curative-intent management for synchronous early-stage tumors, while postoperative genomic profiling can add supportive molecular evidence and inform genetic counseling. Low-VAF renal genomic findings should be interpreted cautiously and in the context of histology and immunophenotype. Long-term surveillance remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.